New Delhi metallo-b-lactamase-1(NDM-1)is capable of hydrolyzing nearly allβ-lactam antibiotics,posing an emerging threat to public health.There are currently less effective treatment options for treating NDM-1 positi...New Delhi metallo-b-lactamase-1(NDM-1)is capable of hydrolyzing nearly allβ-lactam antibiotics,posing an emerging threat to public health.There are currently less effective treatment options for treating NDM-1 positive"superbug",and no promising NDM-1 inhibitors were used in clinical practice.In this study,structure eactivity relationship based on thiosemicarbazone derivatives wassystematically characterized and their potential activities combined with meropenem(MEM)were evaluated.Compounds 19 bg and 19 bh exhibited excellent activity against 10 NDM-positive isolate clinical isolates in reversing MEM resistance.Further studies demonstrated compounds 19 bg and 19 bh were uncompetitive NDM-1 inhibitors with Ki Z 0.63 and 0.44 mmol/L,respectively.Molecular docking speculated that compounds 19 bg and 19 bh were most likely to bind in the allosteric pocket which would affect the catalytic effect of NDM-1 on the substrate meropenem.Toxicity evaluation experiment showed that no hemolysis activities even at concentrations of 1000 mg/m L against red blood cells.In vivo experimental results showed combination of MEM and compound 19 bh was markedly effective in treating infections caused by NDM-1 positive strain and prolonging the survival time of sepsis mice.Our finding showed that compound 19 bh might be a promising lead in developing new inhibitor to treat NDM-1 producing superbug.展开更多
Histone lysine specific demethylase 1(LSD1)has become a potential therapeutic target for the treatment of cancer.Discovery and develop novel and potent LSD1 inhibitors is a challenge,although several of them have alre...Histone lysine specific demethylase 1(LSD1)has become a potential therapeutic target for the treatment of cancer.Discovery and develop novel and potent LSD1 inhibitors is a challenge,although several of them have already entered into clinical trials.Herein,for the first time,we reported the discovery of a series of 5-cyano-6-phenylpyrimidine derivatives as LSD1 inhibitors using flavin adenine dinucleotide(FAD)similarity-based designing strategy,of which compound 14 q was finally identified to repress LSD1 with IC50=183 nmol/L.Docking analysis suggested that compound 14 q fitted well into the FAD-binding pocket.Further mechanism studies showed that compound 14 q may inhibit LSD1 activity competitively by occupying the FAD binding sites of LSD1 and inhibit cell migration and invasion by reversing epithelial to mesenchymal transition(EMT).Overall,these findings showed that compound14 q is a suitable candidate for further development of novel FAD similarity-based LSD1 inhibitors.展开更多
A series of novel 1,2,3-triazole-quinazoline derivatives were synthesized in five steps starting from anthranila- mide by conventional methods. All the title compounds 10a-10r were evaluated for cytotoxic activity aga...A series of novel 1,2,3-triazole-quinazoline derivatives were synthesized in five steps starting from anthranila- mide by conventional methods. All the title compounds 10a-10r were evaluated for cytotoxic activity against four human cancer cell lines （MGC-803, EC-109, MCF-7 and HGC-27） using MTT assay in vitro. Some of the synthe- sized compounds exhibited moderate to potent activity against tested cancer cell lines. Among them, compounds 10h and 10q exhibited excellent growth inhibition against HGC-27 and compound 10m also possessed excellent ac- tivity against MCF-7, with IC50 values less than 1 μmol/L. Especially, compound 10h was more cytotoxic than 5-fluorouracil against all tested four human cancer cell lines.展开更多
Targeting bromodomain-containing protein 4(BRD4) has been proved to be an effective strategy for cancer therapy.To date,numerous BRD4 inhibitors and degraders have been identified,some of which have advanced into clin...Targeting bromodomain-containing protein 4(BRD4) has been proved to be an effective strategy for cancer therapy.To date,numerous BRD4 inhibitors and degraders have been identified,some of which have advanced into clinical trials.In this work,a focused library of new [1,2,4]triazolo [1,5-a]pyrimidine derivatives were discovered to be able to inhibit BRD4.WS-722 inactivated BRD4(BD1/BD2),BRD2(BD1/BD2) and BRD3(BD1/BD2) broadly with the IC_(50) values less than 5 μmol/L.Besides,WS-722 inhibited growth of THP-1 cells with an IC_(50) value of 3.86 μmol/L.Like(+)-JQ1,WS-722 inhibited BRD4 in a reversible manner and enhanced protein stability.Docking studies showed that WS-722 occupied the central acetyl-lysine(Kac) binding cavity and formed a hydrogen bond with Asn140.In THP-1 cells,WS-722 showed target engagement to BRD4.Cellular effects of WS-722 on THP-1 cells were also examined,showing that WS-722 could block c-MYC expression,induce G0/G1 phase arrest and p21 up-regulation,and promote differentiation of THP-1 cells.BRD4 inhibition by WS-722 resulted in cell apoptosis and upregulated expression of cleaved caspased-3/7 and PARP in THP-1 cell lines.The [1,2,4]triazolo[1,5-a]pyrimidine is a new template for the development of new BRD4 inhibitors.展开更多
OBJECTIVE Tumor resistant is the main cause leading to treatment failure.Tumor resistant is related to many aspect of tumor.Jaridon 6 is a new sesquiterpene come from Rabdosia rubescens extacted by our research team p...OBJECTIVE Tumor resistant is the main cause leading to treatment failure.Tumor resistant is related to many aspect of tumor.Jaridon 6 is a new sesquiterpene come from Rabdosia rubescens extacted by our research team previously,have been tested having more obvious advantage than other anti-cancer drugs on tumor-resistant cells including a PTX-resistant gastric cancer cell.But how does the product work?In this paper,we have researched the effect and specific mechanism of Jaridon 6 on gastric-resistant.METHODS In the test,we have adopted vivo and vitro tests to identify the effect of Jaridon 6 on different gastric cancer-resistant cell.The MTT results,Flow test,Western blotting and nude test all verified the anti-cancer of Jaridon 6 on MGC803/PTX gastric resistant cell.We have also used scarifica⁃tion test and transwell tests and Western blotting to testify the inhibition action on EMT by Jaridon 6.The TEM and immu⁃nofluorescence tests have proved the induction autophagy of Jaridon 6.Immunohistochemical tests have been taken to assure the action of Jaridon 6 on EMT,autophagy and PI3K pathway in vivo.RESULTS Jaridon 6 could inhibite the gastric cancer resistant cell in vivo and in vitro.From the mechanism,the inhibiter of 3-MA or LY2940004 have proved the action on PI3K pathway and autophagy by Jaridon 6.Jaridon 6 could induce autophagy in tumor-resistant cells by inhibiting PI3K/AKT pathway.Except that,Jaridon 6 could inhibite the EMT of gastric cancer resistant cell.CONCLUSION Jaridon 6 could be considered for curing gastric cancer resistance,especially for PTX-resistance.Jaridon 6 is a natural autophagy inducer.展开更多
基金supported by National Natural Science Foundation of China(Grant Nos.81903447 for Bing Zhao,81903623 for Yongfang Yao,81703328 for Liying Ma,and 81430085 for Hongmin Liu)National Key Research and Development Project of China(Nos.2016YFA0501800 and 2018YFE0195100 for Hongmin Liu)
文摘New Delhi metallo-b-lactamase-1(NDM-1)is capable of hydrolyzing nearly allβ-lactam antibiotics,posing an emerging threat to public health.There are currently less effective treatment options for treating NDM-1 positive"superbug",and no promising NDM-1 inhibitors were used in clinical practice.In this study,structure eactivity relationship based on thiosemicarbazone derivatives wassystematically characterized and their potential activities combined with meropenem(MEM)were evaluated.Compounds 19 bg and 19 bh exhibited excellent activity against 10 NDM-positive isolate clinical isolates in reversing MEM resistance.Further studies demonstrated compounds 19 bg and 19 bh were uncompetitive NDM-1 inhibitors with Ki Z 0.63 and 0.44 mmol/L,respectively.Molecular docking speculated that compounds 19 bg and 19 bh were most likely to bind in the allosteric pocket which would affect the catalytic effect of NDM-1 on the substrate meropenem.Toxicity evaluation experiment showed that no hemolysis activities even at concentrations of 1000 mg/m L against red blood cells.In vivo experimental results showed combination of MEM and compound 19 bh was markedly effective in treating infections caused by NDM-1 positive strain and prolonging the survival time of sepsis mice.Our finding showed that compound 19 bh might be a promising lead in developing new inhibitor to treat NDM-1 producing superbug.
基金supported by National Natural Science Foundation of China(Project Nos.81430085 and 81773562 for Hongmin Liu,No.81602961 for Yichao Zheng and No.81703328 for Liying Ma)National Key Research Program(Nos.2018YFE0195100 and 2016YFA0501800 for Hongmin Liu,China)+1 种基金Science and Technology Innovation Talents of Henan Provincial Education Department(19IRTSTHN001,China)Scientific Program of Henan Province(No.182102310070,for Liying Ma,China)
文摘Histone lysine specific demethylase 1(LSD1)has become a potential therapeutic target for the treatment of cancer.Discovery and develop novel and potent LSD1 inhibitors is a challenge,although several of them have already entered into clinical trials.Herein,for the first time,we reported the discovery of a series of 5-cyano-6-phenylpyrimidine derivatives as LSD1 inhibitors using flavin adenine dinucleotide(FAD)similarity-based designing strategy,of which compound 14 q was finally identified to repress LSD1 with IC50=183 nmol/L.Docking analysis suggested that compound 14 q fitted well into the FAD-binding pocket.Further mechanism studies showed that compound 14 q may inhibit LSD1 activity competitively by occupying the FAD binding sites of LSD1 and inhibit cell migration and invasion by reversing epithelial to mesenchymal transition(EMT).Overall,these findings showed that compound14 q is a suitable candidate for further development of novel FAD similarity-based LSD1 inhibitors.
文摘A series of novel 1,2,3-triazole-quinazoline derivatives were synthesized in five steps starting from anthranila- mide by conventional methods. All the title compounds 10a-10r were evaluated for cytotoxic activity against four human cancer cell lines （MGC-803, EC-109, MCF-7 and HGC-27） using MTT assay in vitro. Some of the synthe- sized compounds exhibited moderate to potent activity against tested cancer cell lines. Among them, compounds 10h and 10q exhibited excellent growth inhibition against HGC-27 and compound 10m also possessed excellent ac- tivity against MCF-7, with IC50 values less than 1 μmol/L. Especially, compound 10h was more cytotoxic than 5-fluorouracil against all tested four human cancer cell lines.
基金supported by the National Natural Science Foundation of China(Nos.81703326,81773562,81602961 and 81430085)Scientific Program of Henan Province(No.182102310123)China Postdoctoral Science Foundation(Nos.2018M630840 and 2019T120641)。
文摘Targeting bromodomain-containing protein 4(BRD4) has been proved to be an effective strategy for cancer therapy.To date,numerous BRD4 inhibitors and degraders have been identified,some of which have advanced into clinical trials.In this work,a focused library of new [1,2,4]triazolo [1,5-a]pyrimidine derivatives were discovered to be able to inhibit BRD4.WS-722 inactivated BRD4(BD1/BD2),BRD2(BD1/BD2) and BRD3(BD1/BD2) broadly with the IC_(50) values less than 5 μmol/L.Besides,WS-722 inhibited growth of THP-1 cells with an IC_(50) value of 3.86 μmol/L.Like(+)-JQ1,WS-722 inhibited BRD4 in a reversible manner and enhanced protein stability.Docking studies showed that WS-722 occupied the central acetyl-lysine(Kac) binding cavity and formed a hydrogen bond with Asn140.In THP-1 cells,WS-722 showed target engagement to BRD4.Cellular effects of WS-722 on THP-1 cells were also examined,showing that WS-722 could block c-MYC expression,induce G0/G1 phase arrest and p21 up-regulation,and promote differentiation of THP-1 cells.BRD4 inhibition by WS-722 resulted in cell apoptosis and upregulated expression of cleaved caspased-3/7 and PARP in THP-1 cell lines.The [1,2,4]triazolo[1,5-a]pyrimidine is a new template for the development of new BRD4 inhibitors.
文摘OBJECTIVE Tumor resistant is the main cause leading to treatment failure.Tumor resistant is related to many aspect of tumor.Jaridon 6 is a new sesquiterpene come from Rabdosia rubescens extacted by our research team previously,have been tested having more obvious advantage than other anti-cancer drugs on tumor-resistant cells including a PTX-resistant gastric cancer cell.But how does the product work?In this paper,we have researched the effect and specific mechanism of Jaridon 6 on gastric-resistant.METHODS In the test,we have adopted vivo and vitro tests to identify the effect of Jaridon 6 on different gastric cancer-resistant cell.The MTT results,Flow test,Western blotting and nude test all verified the anti-cancer of Jaridon 6 on MGC803/PTX gastric resistant cell.We have also used scarifica⁃tion test and transwell tests and Western blotting to testify the inhibition action on EMT by Jaridon 6.The TEM and immu⁃nofluorescence tests have proved the induction autophagy of Jaridon 6.Immunohistochemical tests have been taken to assure the action of Jaridon 6 on EMT,autophagy and PI3K pathway in vivo.RESULTS Jaridon 6 could inhibite the gastric cancer resistant cell in vivo and in vitro.From the mechanism,the inhibiter of 3-MA or LY2940004 have proved the action on PI3K pathway and autophagy by Jaridon 6.Jaridon 6 could induce autophagy in tumor-resistant cells by inhibiting PI3K/AKT pathway.Except that,Jaridon 6 could inhibite the EMT of gastric cancer resistant cell.CONCLUSION Jaridon 6 could be considered for curing gastric cancer resistance,especially for PTX-resistance.Jaridon 6 is a natural autophagy inducer.
